Although pralsetinib has not yet been approved and would not be offered outside of a clinical trial for the moment, selpercatinib has been recently approved by the US FDA for the treatment for RET-mutant MTC (85). This evidence concerns the gene RET and medullary thyroid gland carcinoma.